The Leukemia & Lymphoma Society (LLS) will again be participating in Gap Inc.'s Give & Get program, which in its first two campaigns last past spring and summer, garnered more than $1 million to support LLS's blood cancer research funding and patient education and support services.
During the campaign, taking place from March 18-21, Gap Inc. will issue downloadable 30% discount coupons participants can use (in-store only) at all Gap Inc. stores, which include Gap, Banana Republic and Old Navy. LLS is among several charities to benefit -- the participants can select the charity of their choice, and 5% of their net purchase will go to that charity.
The coupons can be used as many times as you choose to shop during the days of the promotion and can be shared with as many people as you wish. They are good in stores in both the United States and Canada. So in a time when our communities need it most, your shopping counts for more
This offer is also good at Gap Outlet and Banana Republic Factory Store!
http://www.gapinc.com/giveandget/lls/
To learn more about the Gap's Give & Get program benefiting LLS please visit http://www.gapinc.com/giveandget/lls/.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...